Advertisement
CNSP vs PMN
Which Stock Would AI Choose? CNS Pharmaceuticals (CNSP) vs. ProMIS Neurosciences (PMN) Stock Comparison
Key Takeaways
- CNSP is executing a strategic pivot toward an acquisition-driven pipeline after completing an oversubscribed $22.5 million financing, while PMN is advancing a differentiated Alzheimer's disease candidate with a key clinical readout expected in early 2027.
- The two companies operate in different neuroscience niches, making this a study in contrasting risk profiles rather than a direct product competition.
- PMN carries a substantially larger cash runway and broader analyst coverage, while CNSP remains in an earlier stage of repositioning with its legacy programs winding down.
- Recent market activity has favored PMN on trend consistency and catalyst clarity despite a sharp sympathy sell-off tied to a competing drug's failure.
- Tickeron AI Verdict: Based on observable trend, catalyst, and stability factors, the AI model currently leans toward PMN as the comparatively stronger candidate between the two.
- For additional detail, explore CNSP Major News and CNSP Today's Price Move, as well as PMN Major News and PMN Today's Price Move.
- To see which automated strategies are currently favored for the market environment, visit the Trending AI Robots page.
Introduction
Investors evaluating small- and mid-cap biotechnology names often weigh two very different questions: whether a company has the capital to execute, and whether it has a near-term catalyst capable of re-rating the stock. CNSP (CNS Pharmaceuticals) and PMN (ProMIS Neurosciences) sit at opposite ends of that spectrum. This stock comparison examines their relative performance, market positioning, and momentum to help traders and investors assess which profile better fits the current environment.
CNSP Overview and Recent Performance
CNS Pharmaceuticals is a biotechnology company historically focused on therapies for primary and metastatic brain and central nervous system cancers, including its lead candidate Berubicin for glioblastoma multiforme (GBM), an aggressive form of brain cancer. In recent months, however, the company has pivoted away from a single-asset strategy toward an acquisition-driven growth model centered on neurology and oncology.
Recent market activity has been shaped by a strengthened balance sheet rather than clinical data. The company closed an oversubscribed $22.5 million private placement and reported a cash position of roughly $20 million as of mid-2026, which management states extends its operating runway beyond twelve months. With its legacy GBM programs now winding down and out-licensing discussions underway, sentiment reflects both the improved capital position and the uncertainty of a pipeline that has yet to be rebuilt. The company has said it expects to in-license or acquire one or more assets before year-end, leaving the near-term outlook tied to deal execution rather than trial results.
PMN Overview and Recent Performance
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibodies and vaccines that selectively target toxic misfolded proteins implicated in neurodegenerative diseases. Its lead candidate, PMN310, is being evaluated for early Alzheimer's disease in the PRECISE-AD Phase 1b trial, with 12-month unblinded results expected in the first quarter of 2027.
Recent weeks brought sharp volatility after a competing Alzheimer's treatment, Acumen Pharmaceuticals' Sabirnetug, failed its Phase 2 study. PMN shares declined sharply in sympathy, reflecting concern that the broader approach of targeting toxic amyloid-beta oligomers might be flawed. Analysts, however, largely distinguished PMN310's conformational selectivity, plaque avoidance, and IgG1 (a class of antibody) backbone from the failed drug, with several firms maintaining Buy ratings even as one lowered its price target. The company ended its second quarter with roughly $53 million in cash, expected to fund operations into mid-2027, and reported no cases of ARIA-E (brain swelling associated with amyloid-related imaging abnormalities) in its blinded interim safety data.
Trending AI Robots
For traders seeking a systematic approach to names like CNSP and PMN, Tickeron maintains a library of hundreds of AI Trading Bots that monitor thousands of tickers across different styles, strategies, timeframes, and performance metrics. Because no single strategy fits every market regime, only the most suitable bots for current conditions earn a place in the curated Trending AI Robots section. These bots vary in their holding periods, risk parameters, and the sets of tickers they trade, allowing users to compare statistics before acting. Exploring this selection can help identify automated strategies whose recent performance aligns with your own objectives.
Head-to-Head Comparison
Despite both being neuroscience-focused biotechs, CNSP and PMN present contrasting risk-reward profiles. CNSP is essentially a shell of a pipeline in transition: its legacy GBM assets are being out-licensed, and its forward value depends on successful deal execution, which carries meaningful execution risk but also optionality. PMN, by contrast, owns a specific clinical asset with a defined readout timeline, offering a more conventional binary catalyst.
On capital strength, PMN holds a larger cash balance and a longer stated runway, reducing near-term dilution risk relative to CNSP. On momentum, PMN has experienced higher volatility due to sector-wide read-through from a competitor's failure, whereas CNSP has traded more narrowly around its restructuring narrative. Sector exposure differs meaningfully: CNSP spans oncology and neurology through future acquisitions, while PMN is concentrated in Alzheimer's disease and related proteinopathies.
Tickeron AI Verdict
Weighing observable factors, Tickeron's AI model currently leans toward PMN as the comparatively stronger candidate between the two. The assessment rests on PMN's clearer near-term catalyst, its more substantial cash runway, a differentiated clinical mechanism, and broader institutional analyst support, which together suggest relatively greater trend consistency and catalyst visibility. CNSP's acquisition-driven transformation is directionally positive but introduces execution uncertainty that clouds its near-term momentum. This is a probabilistic, model-based view rather than a definitive forecast, and both names retain elevated biotech-specific risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CNSP is a Hold and PMN is a Hold.
CNSP's Stochastic Oscillator is sitting in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CNSP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +2.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNSP advanced for three days, in 176 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CNSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CNSP as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CNSP turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 36 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CNSP moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CNSP entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.319) is normal, around the industry mean (3.498). P/E Ratio (-0.258) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. CNSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PMN's RSI Indicator ascending out of oversold territory
The RSI Indicator for PMN moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 29 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMN advanced for three days, in 154 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
PMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PMN as a result. In 96 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PMN turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
The 50-day moving average for PMN moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PMN entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.755) is normal, around the industry mean (3.498). P/E Ratio (-0.330) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. PMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CNSP | PMN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 99 | |
PRICE GROWTH RATING 1..100 | 81 | 95 | |
P/E GROWTH RATING 1..100 | 100 | 7 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CNSP's Valuation (48) in the null industry is somewhat better than the same rating for PMN (92). This means that CNSP’s stock grew somewhat faster than PMN’s over the last 12 months.
CNSP's Profit vs Risk Rating (100) in the null industry is in the same range as PMN (100). This means that CNSP’s stock grew similarly to PMN’s over the last 12 months.
CNSP's SMR Rating (99) in the null industry is in the same range as PMN (99). This means that CNSP’s stock grew similarly to PMN’s over the last 12 months.
CNSP's Price Growth Rating (81) in the null industry is in the same range as PMN (95). This means that CNSP’s stock grew similarly to PMN’s over the last 12 months.
PMN's P/E Growth Rating (7) in the null industry is significantly better than the same rating for CNSP (100). This means that PMN’s stock grew significantly faster than CNSP’s over the last 12 months.
| CNSP | PMN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | about 1 month ago 85% | 6 days ago 83% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CNSP’s FA Score shows that 0 FA rating(s) are green while PMN’s FA Score has 1 green FA rating(s).
- CNSP’s FA Score: 0 green, 5 red.
- PMN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CNSP’s TA Score shows that 4 TA indicator(s) are bullish while PMN’s TA Score has 4 bullish TA indicator(s).
- CNSP’s TA Score: 4 bullish, 5 bearish.
- PMN’s TA Score: 4 bullish, 5 bearish.
Price Growth
CNSP (@Biotechnology) experienced а -15.38% price change this week, while PMN (@Biotechnology) price change was +16.72% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
CNSP is expected to report earnings on Nov 13, 2026.
PMN is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CNSP and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNSP has been loosely correlated with PMN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CNSP jumps, then PMN could also see price increases.
| Ticker / NAME | Correlation To CNSP | 1D Price Change % | ||
|---|---|---|---|---|
| CNSP | 100% | -3.02% | ||
| PMN - CNSP | 51% Loosely correlated | -1.73% | ||
| RLYB - CNSP | 46% Loosely correlated | +0.64% | ||
| ORMP - CNSP | 38% Loosely correlated | -0.75% | ||
| AURA - CNSP | 31% Poorly correlated | -0.13% | ||
| PTGX - CNSP | 30% Poorly correlated | +0.26% | ||
More | ||||
PMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, PMN has been closely correlated with ABOS. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if PMN jumps, then ABOS could also see price increases.
| Ticker / NAME | Correlation To PMN | 1D Price Change % | ||
|---|---|---|---|---|
| PMN | 100% | -1.73% | ||
| ABOS - PMN | 76% Closely correlated | -2.95% | ||
| CNSP - PMN | 51% Loosely correlated | -3.02% | ||
| SYRE - PMN | 44% Loosely correlated | -4.15% | ||
| GYRE - PMN | 44% Loosely correlated | -9.03% | ||
| BBIO - PMN | 42% Loosely correlated | +0.95% | ||
More | ||||